Astellas Pharma US will stop distributing Xtandi, a prostate cancer drug that costs about $160,000 each year, to 340B contract pharmacies on Sept. 1, according to a letter obtained by 340B Health. In ...
Astellas Pharma Inc. and Vir Biotechnology Inc. have entered into a global strategic collaboration to advance VIR-5500.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results